Topics:
Breast Cancer • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • HR+ • NCI-CCC Breast Tumor Board Question
For anatomic stage III ER/PR+ breast cancer treated upfront with surgery, how do you decide which adjuvant chemotherapy to offer?
Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help you to decide?
Answer from: Medical Oncologist at Academic Institution
Anatomic stage III breast cancer includes different clinical scenarios ranging from a tumor over 5cm with 1-3 + lymph nodes, tumors with 4 or more + lymph nodes, tumors with chest wall/skin invasion, and inflammatory breast cancer. For the first scenario, a T3N1 post menopausal female with an Oncoty...
Sign in or Register to read more